reatest

Reatest, operating as Rea Diagnostics SA, is a Swiss company founded in 2020, originating from the collaboration between two of Switzerland's recognized institutions, the EPFL (Swiss Federal Institute of Technology Lausanne) and the CHUV (Lausanne University Hospital). The company is dedicated to addressing the challenge of preterm birth, which stands as a primary cause of infant mortality globally.

The core of Reatest's business is the development of technology for at-home monitoring for women at risk of a premature birth. The company's flagship product is a Smart Sanitary Pad, or Smart Panty Liner, designed to detect specific biochemical markers in vaginal secretions that indicate an elevated risk of preterm delivery. If a test yields a negative result, it suggests there is no imminent risk of delivery within the subsequent seven days. This product provides an early alert system for doctors, enabling them to take necessary medical actions. The team's work is clinically guided by Professor David Baud, the Head of Obstetrics at the Lausanne University Hospital.

Reatest operates in the health-tech and medical diagnostics market, serving both B2B and B2C segments. Its business activities encompass research and development, production, and the sales and marketing of its own products. The company targets pregnant women and their healthcare providers as its primary client base. Having received support from entities like Venture Kick and VentureLab, Reatest is focused on modernizing the diagnostic tools available for anticipating preterm birth risks.

Keywords: preterm birth, medical diagnostics, health-tech, smart sanitary pad, at-home monitoring, women's health, clinical validation, EPFL spinoff, medical devices, pregnancy monitoring